Skip to content

Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States – a Rural and Urban Comparison

Research output: Contribution to journalArticle

Original languageEnglish
Article numberkwz097
Pages (from-to)1539–1551
Number of pages13
JournalAmerican Journal of Epidemiology
Issue number8
DateAccepted/In press - 2 Apr 2019
DatePublished (current) - 31 May 2019


In the U.S. Hepatitis C virus (HCV) transmission is increasing among people who inject drugs (PWID). Many regions have insufficient prevention intervention coverage. Using modelling, we investigate the impact of scaling-up prevention and treatment interventions on HCV transmission among PWID in Perry County, Kentucky (PC), and San Francisco, California (SF), where HCV sero-prevalence among PWID is >50%. A greater proportion of PWID access medication-assisted treatment (MAT) or syringe service programs (SSP) in urban SF (established community) than rural PC (young, expanding community). We model the proportion of HCV-infected PWID needing HCV-treatment annually to reduce HCV-incidence by 90% by 2030, with and without MAT scale-up (50% coverage, both settings) and SSP scale-up (PC only) from 2017. With current MAT&SSP coverage during 2017-2030, HCV-incidence will increase in PC (21.3 to 22.6 per 100 person-years (/100pyrs)) and decrease in SF (12.9 to 11.9/100pyrs). With concurrent MAT&SSP scale-up, 5%/year of HCV-infected PWID need HCV-treatment in PC to achieve incidence targets; 13%/year without MAT&SSP scale-up. In SF, a similar proportion need HCV-treatment (10%/year) irrespective of MAT scale-up. Reaching the same impact by 2025 requires increases in treatment rates of 45-82%. Achievable provision of HCV-treatment, alongside MAT&SSP scale-up (PC) and MAT scale-up (SF), could reduce HCV-incidence.

    Research areas

  • direct-acting-antiviral HCV-treatment, Hepatitis C virus, medication-assisted treatment, modelling, persons who inject drugs, syringe service programs



  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Oxford University Press at Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 593 KB, PDF document

    Embargo ends: 31/05/20

    Request copy


View research connections

Related faculties, schools or groups